Experimental cocktail aims to outsmart Hard-to-Treat breast cancer

NCT ID NCT06959537

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This early-phase trial is testing a new combination of three drugs—cyclophosphamide, axatilimab, and retifanlimab—in people with metastatic triple negative breast cancer that has stopped responding to standard treatments. The main goal is to find the safest dose of the new combination. About 24 participants will be enrolled at M.D. Anderson Cancer Center.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cyclophosphamide, axatilimab, and retifanlimab
What this could lead to: If this works, it could point toward a new treatment option for people with metastatic triple negative breast cancer who have run out of standard options.
What could go wrong: This is a very early phase 1 trial with only 24 people, focused on finding the right dose and checking safety. It is too soon to know if the combination will actually shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm inflammatory breast carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

The University of Texas M. D. Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.